Together Intra-Tumor Hypoxia and Macrophagic Immunity Are Driven Worst Outcome in Pediatric High-Grade Osteosarcomas.
Fiche publication
Date publication
mars 2022
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DONTENWILL Monique, Pr ENTZ-WERLE Natacha, Dr LHERMITTE Benoît
Tous les auteurs :
Nazon C, Pierrevelcin M, Willaume T, Lhermitte B, Weingertner N, Marco AD, Bund L, Vincent F, Bierry G, Gomez-Brouchet A, Redini F, Gaspar N, Dontenwill M, Entz-Werle N
Lien Pubmed
Résumé
Osteosarcomas (OTS) represent the most common primary bone cancer diagnosed in adolescents and young adults. Despite remarkable advances, there are no objective molecular or imaging markers able to predict an OTS outcome at diagnosis. Focusing on biomarkers contributing broadly to treatment resistance, we examine the interplay between the tumor-associated macrophages and intra-tumor hypoxia.
Mots clés
biomarkers, hypoxia, macrophages, magnetic resonance imaging, osteosarcoma, pediatric
Référence
Cancers (Basel). 2022 Mar 14;14(6):